Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

chevron_leftPreviosly
Lice feel the itch over Hatchtech deal
01 November 2013

You may also like

08 October 2012

Vaxxas Appoints David Hoey as Company’s First CEO

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

16 May 2018

Biomedical Translation Fund invests in further development of total artificial heart device

29 May 2020

Vaxxas announces that MSD exercises option to apply novel immune system activation platform for vaccine candidate

25 September 2013

charmhealth appoints Health-IT Expert to the Board

18 October 2016

Clinical Genomics Strenghtens it’s Leadership Team with Multiple Key Appointments

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor